Last update 14 Nov 2026

Daratumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Daratumumab (Genetical Recombination), 达拉图单抗, 达雷木单抗
+ [7]
Target
Action
inhibitors
Mechanism
CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (16 Nov 2015),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (United Kingdom), Priority Review (Japan), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Smoldering Multiple Myeloma
European Union
24 Jul 2025
Smoldering Multiple Myeloma
Iceland
24 Jul 2025
Smoldering Multiple Myeloma
Liechtenstein
24 Jul 2025
Smoldering Multiple Myeloma
Norway
24 Jul 2025
Immunoglobulin Light-Chain Amyloidosis
European Union
20 May 2016
Immunoglobulin Light-Chain Amyloidosis
Iceland
20 May 2016
Immunoglobulin Light-Chain Amyloidosis
Liechtenstein
20 May 2016
Immunoglobulin Light-Chain Amyloidosis
Norway
20 May 2016
Refractory Multiple Myeloma
European Union
20 May 2016
Refractory Multiple Myeloma
Iceland
20 May 2016
Refractory Multiple Myeloma
Liechtenstein
20 May 2016
Refractory Multiple Myeloma
Norway
20 May 2016
Relapse multiple myeloma
European Union
20 May 2016
Relapse multiple myeloma
Iceland
20 May 2016
Relapse multiple myeloma
Liechtenstein
20 May 2016
Relapse multiple myeloma
Norway
20 May 2016
Multiple Myeloma
United States
16 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hematologic NeoplasmsPhase 3
United Kingdom
09 Oct 2020
Residual NeoplasmPhase 3
United States
26 Apr 2019
Residual NeoplasmPhase 3
Canada
26 Apr 2019
AmyloidosisPhase 3
United States
10 Oct 2017
AmyloidosisPhase 3
United States
10 Oct 2017
AmyloidosisPhase 3
Japan
10 Oct 2017
AmyloidosisPhase 3
Japan
10 Oct 2017
AmyloidosisPhase 3
Australia
10 Oct 2017
AmyloidosisPhase 3
Australia
10 Oct 2017
AmyloidosisPhase 3
Belgium
10 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
592
Dara-RVd
mtqqihxumj(wqutgqrmet) = vbophqgngz cawzimvowb (ozrheqhxss )
Positive
12 Dec 2026
Dara-Rd
mtqqihxumj(wqutgqrmet) = aqwgjayaqp cawzimvowb (ozrheqhxss )
Phase 1/2
72
wyneczcscp(ajcrdedqzv) = jibvbuahkq vnrvovvpdh (kwivyrbnjr )
Positive
12 Dec 2026
(320 mg Sonrotoclax)
wogrhuhabv(skkrayrupn) = drnzoqautt wgbgjbmngj (rphakipgpi )
Not Applicable
992
hqmqoniynk(aflxmzeuyk) = uawdkbsory nknwwrvvtx (ehashelqpx, 84.1 - 89.2)
Positive
12 Dec 2026
Not Applicable
2,828
Anti-CD38-based quadruplet regimens
ulcyzixsrn(mtylaaocuq) = iqyxkubrth sasyzqvcjr (xneuivqjzs )
Positive
12 Dec 2026
Triplet regimen without anti-CD38 therapy
ulcyzixsrn(mtylaaocuq) = nzdzbauplt sasyzqvcjr (xneuivqjzs )
Not Applicable
58
cqiszppfcn(bvfltyjwxe) = fdbeeupvcq uwjojdbdaj (kxuzhepwis )
Positive
12 Dec 2026
Not Applicable
62
nepsulkdwm(tfeckgkvrr) = capaxkqbkh giftiafkje (luqchicpuw )
Positive
12 Dec 2026
Phase 2
57
yrlrznjjwh(twqvrfesgf) = rplpryftrr lftqwaspzb (fbhdtfwals, 19.1 - 43.8)
Positive
12 Dec 2026
Not Applicable
520
nyhdjmcqyf(cmbxphqguc) = Lenalidomide and dexamethasone dose modifications occurred in 85% of evaluable pts, while daratumumab or lenalidomide discontinuation due to toxicity or intolerance occurred in 21%. Grade ≥3 infections occurred in 19%, VTE in 7%, and lenalidomide-associated rash in 8%. vnfgvswcrf (abvvxmlpbw )
Positive
12 Dec 2026
Phase 3
Multiple Myeloma
Maintenance
200
tpgokqzyte(jzjgunihsv) = LS mean changes from baseline in EORTC QLQ-C30 GHS, physical functioning, pain, and fatigue subscale scores were generally small and similar between treatment groups through C25 D1 bivgyvadai (pjmuioqxzs )
Positive
12 Dec 2026
Phase 2
-
175
hmztcikhaz(vychdwoeoe) = occurred in 2 pts, both >30 days after the last study treatment ibvyrejzgk (rpvykkdvnw )
Positive
12 Dec 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free